So if HCV is one of the few areas going forward?

[Anonymous]

How come NO ONE can tell us anything about what is going on in MRL?

 

[Anonymous]

This might help answer your question

http://www.fool.com/investing/gener...sses-that-may-become-obsolete-within-3-y.aspx

 

[Anonymous]

This might help answer your question

http://www.fool.com/investing/gener...sses-that-may-become-obsolete-within-3-y.aspx

KW is doing due diligence on an In-licensed Nucleotide Polymerase Inhibitor that we think has promise and is ready to go into late stage trials. Be Well.

 

[Anonymous]

KW is doing due diligence on an In-licensed Nucleotide Polymerase Inhibitor that we think has promise and is ready to go into late stage trials. Be Well.

LMAO. Ya ok. Only about 2 years too late by the time it comes close to launching if, and it's a big if, it doesn't show the same liver problems the rest of the poly agents have, except for Gilead's

 

[Anonymous]

LMAO. Ya ok. Only about 2 years too late by the time it comes close to launching if, and it's a big if, it doesn't show the same liver problems the rest of the poly agents have, except for Gilead's

This one is Better than Gilead's, even their new ones. MUCH BETTER!

 

[Anonymous]

This one is Better than Gilead's, even their new ones. MUCH BETTER!

Merck just does not have the expertise in the Nucleotide space. Yes, we pioneered this technology. My mentor was the RCD on the project. However, we just could not get it right. Now we will Buy what we need from an early competitor in the NS5b space. Chow!

 

[Anonymous]

This one is Better than Gilead's, even their new ones. MUCH BETTER!

much better than a once a day regime that delivers 100% SVR's? again, ya ok.

 

[Anonymous]

much better than a once a day regime that delivers 100% SVR's? again, ya ok.

MRL restructuring. Studies take 12 weeks, sit tight